939040-19-4

Basic information

• Product Name: 4-chloro-5-nitro-6-(o-tolyl)pyrimidine
• Synonyms: 4-chloro-5-nitro-6-(o-tolyl)pyrimidine
• CAS NO: 939040-19-4
• Molecular Weight: 249.656
• Mol File: 939040-19-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-chloro-5-nitro-6-(o-tolyl)pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-5-nitro-6-(o-tolyl)pyrimidine(939040-19-4)
• EPA Substance Registry System: 4-chloro-5-nitro-6-(o-tolyl)pyrimidine(939040-19-4)

Safety Data

• Hazardous Substances Data: 939040-19-4(Hazardous Substances Data)

Upstream product

• 4316-93-2 4,6-dichloro-5-nitropyrimidine 
• 16419-60-6 2-Methylphenylboronic acid 

Downstream Products

• 1466574-36-6 N-methyl-N-(4-(o-tolyl)pyrimidin-5-yl)-3,5-bis-trifluoromethylbenzamide 
• 939040-41-2 N⁴-(2,4-dimethoxyphenyl)-6-o-tolyl-pyrimidine-4,5-diamine 
• 939040-56-9 N⁴-(2,6-difluorophenyl)-6-o-tolyl-pyrimidine-4,5-diamine 
• 939040-40-1 N⁴-(2,4-difluorophenyl)-6-o-tolyl-pyrimidine-4,5-diamine 
• 939040-39-8 N⁴-(2,6-dimethylphenyl)-6-o-tolyl-pyrimidine-4,5-diamine 
• 939040-33-2 (2,4-dimethoxyphenyl)-(5-nitro-6-o-tolyl-pyrimidine-4-yl)-amine 
• 939040-29-6 (2,6-dimethylphenyl)-(5-nitro-6-o-tolyl-pyrimidine-4-yl)-amine 
• 939040-31-0 (2,6-difluorophenyl)-(5-nitro-6-o-tolyl-pyrimidine-4-yl)-amine 
• 1352140-98-7 4-(o-tolyl)pyrimidin-5-ylamine 

Relevant articles and documents

Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors

Based on the purine scaffold of ATP, derivatives of 6,9-diarylpurine-8-one were prepared and tested for their ability to inhibit p38 MAP kinase, a key enzyme in the cellular regulation of proinflammatory cytokines. The inhibitor design combines the purine

1,2- PYRIDAZINE, 1,6- PYRIDAZINE OR PYRIMIDINE - BENZAMIDE DERIVATIVES AS GPBAR1 MODULATORS

This invention relates to novel 1,2-pyridazines, 1,6-pyridazines or pyrimidines of the formula I wherein B1 to B3 and R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acc